An Open-label, Parallel-group, Randomized, Multicenter Study to Assess the Safety and Efficacy of Vilaprisan in Subjects With Uterine Fibroids Versus Standard of Care
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 19 Dec 2018
At a glance
- Drugs Vilaprisan (Primary)
- Indications Uterine leiomyoma
- Focus Registrational; Therapeutic Use
- Acronyms ASTEROID 6
- Sponsors Bayer
- 10 Dec 2018 Status changed from recruiting to active, no longer recruiting.
- 26 Oct 2018 Planned End Date changed from 25 Jan 2022 to 13 Sep 2021.
- 26 Oct 2018 Planned primary completion date changed from 25 Jan 2022 to 13 Sep 2021.